Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect In Phase IIa Trial In Nocturia
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.

Rush University Medical Center Hosts Conference Examining Chicago Breastfeeding Rates And Ways To Reduce The Disparities
Over 100 certified breastfeeding peer counselors, lactation consultants, nurses, physicians, dietitians and community health workers are expected to gather at Rush University Medical Center on Thursday, August 6 from 8 a.m. until 1 p.m. in Room 500 at 1725 W. Harrison Street, Chicago, to attend the Griffin Inaugural Conference on Breastfeeding: The Primary Foundation for Health.
News of the day
National HIV/AIDS Advocate, Physician Joel Weisman Dies In California
Joel Weisman, "one of the first physicians to detect the AIDS epidemic and who became a national advocate for AIDS research, treatment and prevention," died on Saturday at his home in Westwood, Calif., the Los Angeles Times reports. Weisman was 66. Weisman was a general practitioner in southern California when in 1980 he first saw three ill gay men with a set of mysterious symptoms. He later contributed to the June 5, 1981 CDC Morbidity and Mortality Weekly Report, which "signaled the official start of the epidemic that the federal agency later named acquired immunodeficiency syndrome," according to the Times. Weisman was the founding chair of AIDS Project Los Angeles in 1983, helped organize the first dedicated hospital AIDS unit in Southern California and was an original board member of amfAR, the Foundation for AIDS Research (Woo, 7/23).
Cardiovascular

Oncological Results, Functional Outcomes, Quality-of-Life - Radical Prostatectomy Or External Beam Radiation Therapy For Localized Prostate Cancer

UroToday.com - Most recently, health-related quality-of-life (HRQOL) after definitive local therapy for prostate cancer has been argued in the patient group with an oncological risk category. [1] Prior to such controversy, we thought that posttreatment HRQOL issues or functional outcomes possibly vary among oncological risk categories, and compared both oncological and functional outcomes between patients receiving radical prostatectomy (RP) and those undergoing external beam radiation therapy (EBRT) with risk stratification. [2] Indeed, we found that the low- and intermediate-risk patients in the RP group reported poorer urinary function than those in the EBRT group. However, the sexual function of the low-risk patients in the EBRT group was poorer than that of the RP patients at same risk. Not only in general populations but also in our patient series, sexual function of the low-risk EBRT patients, who were older than those indicated for RP, might be more affected by irradiation. Moreover, in the present study, the fraction of patients receiving neoadjuvant androgen deprivation therapy (ADT) was larger in the EBRT group. Thus, the results additionally suggested the need for further studies regarding the influence of age and ADT on general HRQOL and functional outcomes in patients after interventions for prostate cancer. [3] The present study also showed that biochemical recurrence/progression was not associated with general HRQOL or functional outcomes in any group or risk category. Although all our patients showing biochemical recurrence were informed about their unfavorable disease condition, biochemical recurrence/progression was thought to have little impact on general HRQOL or functional outcomes. This is interesting when considering different risk estimated at diagnosis and actually different HRQOL/functional results in each risk group. It has been suggested that the posttreatment HRQOL score surveyed using questionnaires possibly appear better in patients without disease recurrence, simply because they are happy without disease. [4] Yet, our study employing definite risk stratification showed that biochemical progression does not have an influence on the HRQOL score reported with self-rating questionnaires. Thus, a longitudinal large study is warranted for the influence of biochemical recurrence on general HRQOL and functional outcomes as well as those evaluated according to risk stratification in patients with prostate cancer, who are managed with various approaches. References [1] Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol. 2009 May 20. [Epub ahead of print] [2] Takizawa I, Hara N, Nishiyama T, Kaneko M, Hoshii T, Tsuchida E, Takahashi K. Oncological results, functional outcomes and health-related quality-of-life in men who received a radical prostatectomy or external beam radiation therapy for localized prostate cancer: a study on long-term patient outcome with risk stratification. Asian J Androl. 2009;11(3):283-90. [3] Kang SH, Kim JW, Bae JH, Park HS, Moon DG, et al. Targeted-cryosurgical ablation of the prostate with androgen deprivation therapy: quality of life in high-risk prostate cancer patients. Asian J Androl 2006; 8: 629-36. [4] Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol. 2008;26:17-34. Written by Noboru Hara, MD, PhD as part of Beyond the Abstract on UroToday.com UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009